John Parkinson

Pfizer CEO, Albert Bourla, said in nationally televised interview that it is necessary to fend off waning protection.

Face covering determinations will now be made based off hospitalizations, rather than case counts, among other metrics.

This vaccine will add another alternative to the current vaccines on the market if approved in US and Europe.

Three doses ought to offer ample protection from infection, the companies say.

Vaccinations continue to be the key strategy. The administration is looking at ways to encourage adults to get booster doses, as well as opening family clinics to get children vaccinated, and adults booster doses.

The move is the first step in paving the way for younger children to get COVID-19 vaccines.

Enough of the Pfizer/BioNTech vaccine has been secured to offer vaccinations for everyone in this age group.

The company reports that for fully vaccinated study participants aged 12-17 (2 doses administered) no cases of COVID-19 were reported.

This non-prescription test allows users to perform and get results themselves without a medical provider or laboratory needed.

Data show that AstraZeneca’s AZD1222 vaccine met its endpoint and the company is preparing regulatory submission for conditional or early approval.

A letter signed by 80 researchers says the concept put forth by the Great Barrington Declaration is “a dangerous fallacy.”

The U.S. government will pay Pfizer and BioNTech $1.95 billion upon the receipt of the first 100 million doses, following US Food and Drug Administration (FDA) authorization or approval. The U.S. government also can acquire up to an additional 500 million doses.

Biopharmaceutical New Technologies (BioNTech) for the investigational vaccines BNT162b1 and BNT162b1. The vaccines are the result of a joint research venture between Pfizer and Biopharmaceutical New Technologies (BioNTech).